Marty
Well-known member
As I have noted here in earlier posts, the physicians I work with prefer to "hold" rather than bridge prior to colonoscopy, and other procedures. Here is some evidence supporting them. My cardiologist says that in all his years of practise he has had no problems.
Dangers of Interrupting Warfarin Therapy Weighed
Warfarin therapy may be interrupted with low risk for as long as 5 days for
minor invasive procedures, but vigilance is required, the Archives of Internal
Medicine reports.
Industry-funded researchers prospectively evaluated outcomes in some 1000
patients whose warfarin therapy was interrupted, most often for 5 days or fewer
and to accommodate requirements for colonoscopy or oral/dental surgery. Bridging
therapy (perioperative heparin) was used in less than 10% of cases.
Seven patients (less than 1%) suffered thromboembolism within 30 days of the
procedure; none had received bridging therapy. Of the 23 patients who had
bleeding episodes within 30 days, nearly two-thirds had received bridging
therapy.
The authors conclude that, until a trial of bridging versus nonbridging therapy
is performed, physicians may use these results to "weigh the risks and benefits
of different perioperative treatment strategies for patients taking warfarin."
Link(s):
Archives of Internal Medicine article (Free abstract; full text requires
subscription) http://click.jwatch.org/cts/click?
Dangers of Interrupting Warfarin Therapy Weighed
Warfarin therapy may be interrupted with low risk for as long as 5 days for
minor invasive procedures, but vigilance is required, the Archives of Internal
Medicine reports.
Industry-funded researchers prospectively evaluated outcomes in some 1000
patients whose warfarin therapy was interrupted, most often for 5 days or fewer
and to accommodate requirements for colonoscopy or oral/dental surgery. Bridging
therapy (perioperative heparin) was used in less than 10% of cases.
Seven patients (less than 1%) suffered thromboembolism within 30 days of the
procedure; none had received bridging therapy. Of the 23 patients who had
bleeding episodes within 30 days, nearly two-thirds had received bridging
therapy.
The authors conclude that, until a trial of bridging versus nonbridging therapy
is performed, physicians may use these results to "weigh the risks and benefits
of different perioperative treatment strategies for patients taking warfarin."
Link(s):
Archives of Internal Medicine article (Free abstract; full text requires
subscription) http://click.jwatch.org/cts/click?